Morris Kandinov LLP is representing Camac Fund, LP in an action against the board of directors of Forte Biosciences, Inc. and other defendants who attempted to fix the vote in advance of the company’s annual meeting.

Morris Kandinov LLP is representing an investor in an action against Forte Biosciences Inc.’s board for breaching its fiduciary duties by diluting stockholders’ voting power to protect incumbents’ positions.

Morris Kandinov LLP is representing investors in TuSumple Holdings Inc. in a consolidated litigation in Delaware.

After being sued, the board of trustees of the First Trust closed-end funds announced that they have “determined to rescind the control share provisions.”

Morris Kandinov LLP represents investors in connection with vote rigging in a closed-end fund trustee election.

U.S. District Court denies defendants’ motion to dismiss in dispute over $32.5 million termination fee payment.

The Delaware Chancery Court rejected an interlocutory appeal of the Court’s prior ruling denying defendants’ motion to dismiss, permitting discovery to proceed in the case.

Morris Kandinov LLP represents investors in a dispute over a SPAC’s remaining assets in a dissolution after a failed transaction resulted in a termination fee.

Matt Levine writes about the key issue raised by three new SPAC cases filed by Morris Kandinov LLP: “Who gets the cash: the public shareholders, or the sponsors?”

The court denies defendants’ motion to dismiss claims arising from a closed-end fund’s collapse and subsequent unfair merger.